Section Arrow
GRI.NASDAQ
- GRI Bio Inc.
Quotes are at least 15-min delayed:2025/09/04 04:00 EDT
Pre Market
Last
 --
-- (--)
Bid
1.39
Ask
1.49
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 1.46
+0.06 (+4.29%)
Day High 
1.48 
Prev. Close
1.4 
1-M High
1.57 
Volume 
47.60K 
Bid
1.39
Ask
1.49
Day Low
1.38 
Open
1.39 
1-M Low
1.15 
Market Cap 
3.52M 
Currency USD 
P/E 0.02 
%Yield -- 
10-SMA 1.41 
20-SMA 1.36 
50-SMA 1.54 
52-W High 30.43 
52-W Low 1.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
90.80/-2.17
Enterprise Value
3.59M
Balance Sheet
Book Value Per Share
1.32
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
Pre Market -- -- --
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
Pre Market 0.0572 +0.0046 +8.75%
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
Pre Market 0.3497 -0.0202 -5.46%
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
Pre Market 2.52 0 0.00%
STTKShattuck Labs1.28+0.27+26.73%-- 
Pre Market 1.35 +0.07 +5.47%
Quotes are at least 15-min delayed:2025/09/04 04:00 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.